Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...